| |
• |
|
Data from the multiple ascending dose (MAD) cohorts of this study expected to be shared in the second half of
2024 |
Corporate
| |
• |
|
Completed an underwritten public offering of common stock in June 2024 for $178.0 million in gross proceeds
|
Second Quarter 2024 Financial Results:
| |
• |
|
Cash Position: Cash, cash equivalents, and marketable securities were $500.9 million as of
June 30, 2024, which are expected to fund our operational plans well into 2027. |
| |
• |
|
Research and Development Expenses: R&D expenses were $23.5 million for the quarter ended
June 30, 2024, as compared to $12.1 million for the quarter ended June 30, 2023. The increase in R&D expenses were primarily driven by the progression of Disc’s portfolio, including bitopertin’s clinical studies and drug
manufacturing, and advancing our DISC-0974 and DISC-3405 programs in the clinic, and increased headcount. |
| |
• |
|
General and Administrative Expenses: G&A expenses were $7.4 million for the quarter ended
June 30, 2024, as compared to $5.2 million for the quarter ended June 30, 2023. The increase in G&A expenses was primarily due to increased headcount. |
| |
• |
|
Net Loss: Net loss was $26.4 million for the quarter ended June 30, 2024, as compared to
$15.9 million for the quarter ended June 30, 2023. |
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for
patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a
wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Available Information
Disc announces material
information to the public about the Company, its products and services, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts and the
investor relations section of the Company website at ir.discmedicine.com in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations
under Regulation FD.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, express or implied statements regarding Disc’s expectations with respect to its AURORA Phase 2 and BEACON Phase 2 clinical trials of bitopertin and the results thereof, its Phase 1b/2 clinical trial of DISC-0974 in patients with
MF and NDD-CKD patients with anemia, its initial SAD data in its Phase 1 clinical trial of DISC-3405 in healthy volunteers; and projected timelines for the initiation and completion of its clinical trials,
anticipated timing of release of data, and other clinical activities; and Disc’s belief about operating expenses and that it will have capital to fund Disc well into 2027. The use of words such as, but not limited to, “believe,”
“expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,”
“seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are